New York, NY, January 23, 2014 --(PR.com
)-- Creative Biolabs chief staff scientist said that “Theoretically speaking, biosimilars have great potential to cut development costs, expand patient access to biologics, and improve affordability. But actually it is hard to achieve with issues like intellectual property stumble and the complex production process. That is to say the biopharmaceutical industry is therefore pushing forward aggressively to overcome the difficulties and it is indeed making progress. In the setting, we have developed a wide range of biosimilar stable cell lines using our proprietary gene screening and amplification system.”
Office of Research & Development Alliances, Creative Biomart recalled that “These issues led to expensive prices in market. However I believe the solution is arriving since some of the stumbles are beginning to wither away, issue that favors the start-up of producing bio-similar proteins with a more innovative and competitive biological process.”
The company bio-similar cell lines including:
- Human MAb Cell Lines, see http://www.creativebiomart.net/producttypelist_163_1_1_Human.htm
- Pseudomonas aeruginosa MAb Cell Line, see http://www.creativebiomart.net/description_145131_163.htm
For more information, visit http://www.creative-biolabs.com/Bio-similar-Cell-Lines.html.
About Creative Biolabs
Creative Biolabs is the leading custom service provider that has extensive experience in various antibody production and engineering fields.
About Creative Biomart
Creative Biomart is leading biotech company that provides quality recombinant proteins, diagnostic antibodies and antigens, diagnostic enzymes and pharmaceutical enzymes to the research community of biology, clinical research, molecular diagnostics and biopharmaceutical drug development.